🇺🇸 Dasatinib Tablets in United States
12 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 12
Most-reported reactions
- Chylothorax — 2 reports (16.67%)
- Drug Ineffective — 2 reports (16.67%)
- Bone Marrow Failure — 1 report (8.33%)
- Drug Effect Incomplete — 1 report (8.33%)
- Drug Intolerance — 1 report (8.33%)
- Drug Resistance — 1 report (8.33%)
- Escherichia Sepsis — 1 report (8.33%)
- Growth Retardation — 1 report (8.33%)
- Leukaemia Recurrent — 1 report (8.33%)
- Multiple Organ Dysfunction Syndrome — 1 report (8.33%)
Other Oncology approved in United States
Frequently asked questions
Is Dasatinib Tablets approved in United States?
Dasatinib Tablets does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Dasatinib Tablets in United States?
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the originator. The local marketing authorisation holder may differ — check the official source linked above.